ARTICLE | Clinical News

Angiomax bivalirudin: Phase III data; marketed to treat unstable angina in patients undergoing angioplasty in the U.S. and New Zealand

December 3, 2001 8:00 AM UTC

MDCO said international Phase III data published in the American Heart Journal comparing Angiomax to heparin showed Angiomax reduced the risk of death, MI or urgent revascularization by 22% after 7 da...